Retrospective study of hyponatremia in gastric cancer patients treated with a combination chemotherapy of 5-fluorouracil and cisplatin: A possible warning sign of severe hematological toxicities?

Japanese Journal of Clinical Oncology

Volumn 31, Issue 8, 2001, Pages 382-387

  Boku, Narikazu ^a   Ohtsu, Atsushi ^a   Nagashima, Fumio ^a   Muto, Manabu ^a   Shinkai, Tetsu ^a   Yoshida, Shigeaki ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

5 Fluorouracil; Cisplatin; Gastric cancer; Hematological toxicities; Hyponatremia

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; CORTICOSTEROID; CREATININE; DEXAMETHASONE; DIURETIC AGENT; FLUOROURACIL; GRANISETRON; NITROGEN; SODIUM; UREA;

ADULT; ADVANCED CANCER; ARTICLE; ASCITES; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG INFUSION; FEMALE; FEVER; HUMAN; HYDRATION; HYPONATREMIA; INCIDENCE; LABORATORY TEST; LEUKOPENIA; MALE; NAUSEA AND VOMITING; PATIENT CODING; PLEURA EFFUSION; PROBABILITY; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SODIUM BLOOD LEVEL; STATISTICAL ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; URINE VOLUME;

EID: 0034786757     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye085     Document Type: Article

References (18)

1. Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer
2. A phase II study of combined 5-fluorouracil, doxorubicin and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas
3. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer
4. A phase II study in advanced gastric cancer using epirubicin and cisplatin in combination with continuous 5-fluorouracil (ECF)
5. A phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer
6. FAMTX versus etoposide, doxorubicin and cisplatin: A randomized trial in gastric cancer
7. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG)
8. Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinomas: A phase II trial with prognostic factor analysis
9. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer
10. Phase III study of UFT + MMC versus 5-FU + CDDP versus 5-FU alone in patients with advanced gastric cancer. JCOG study 9205
11. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency
12. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity
13. Pharmacogenetics of cancer therapy: Getting personal
14. Modulation of sodium-coupled uptake and membrane fluidity by cisplatin in renal proximal tubular cells in primary culture and brush-border membrane vesicles
15. Cisplatin-induced hyponatremia and renal sodium wasting
16. Basis principles of ROC analysis
17. Hyponatremia related to medical anticancer treatment
18. Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach